- Home
- DUO vs CDIO Comparison
DUO vs CDIO Comparison
Compare DUO & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DUO | CDIO |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | China | United States |
| Employees | N/A | 17 |
| Industry | Real Estate | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.0M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | DUO | CDIO |
|---|---|---|
| Price | $1.38 | $1.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.8K | ★ 113.4K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $171,906.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.18 |
| 52 Week High | $5.34 | $7.91 |
Technical Indicators
Market Signals| Indicator | DUO | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 67.53 | 40.38 |
| Support Level | $1.25 | $1.69 |
| Resistance Level | $1.78 | $2.03 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 76.51 | 31.92 |
Price Performance
Historical ComparisonAbout DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.